Lymphoblastic Lymphoma Clinical Trials

60 recruitingLast updated: June 18, 2026

There are 60 actively recruiting lymphoblastic lymphoma clinical trials across 33 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Philadelphia, Pennsylvania, United States, Seattle, Washington, United States. Updated daily from ClinicalTrials.gov.


Lymphoblastic Lymphoma Trials at a Glance

60 actively recruiting trials for lymphoblastic lymphoma are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 29 trials, with the heaviest enrollment activity in Houston, Philadelphia, and Seattle. Lead sponsors running lymphoblastic lymphoma studies include M.D. Anderson Cancer Center, Children's Oncology Group, and Baylor College of Medicine.

Browse lymphoblastic lymphoma trials by phase

Treatments under study

About Lymphoblastic Lymphoma Clinical Trials

Looking for clinical trials for Lymphoblastic Lymphoma? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphoblastic Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphoblastic Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 60 trials

Recruiting
Phase 1

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

Lymphoblastic LymphomaAcute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc24 enrolled4 locationsNCT07586618
Recruiting
Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic Lymphoma+1 more
Children's Oncology Group80 enrolled157 locationsNCT02981628
Recruiting

CAYA Cancer Prospective Cohort Study

CancerPediatric CancerAcute Lymphoblastic Leukemia ALL+1 more
Resonance, Inc.6,000 enrolled3 locationsNCT07632014
Recruiting
Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 1Phase 2

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

B-cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD115 enrolled1 locationNCT05480449
Recruiting
Phase 2

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma
M.D. Anderson Cancer Center80 enrolled1 locationNCT02877303
Recruiting
Phase 1

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-non-Hodgkin Lymphoma
Baylor College of Medicine27 enrolled2 locationsNCT07220993
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

OsteosarcomaRecurrent LymphomaLymphoblastic Lymphoma+4 more
Children's Oncology Group420 enrolled79 locationsNCT01790152
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 2

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Wugen, Inc.125 enrolled15 locationsNCT06514794
Recruiting
Not Applicable

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

LeukemiaAcute Myeloid Leukemia in RemissionLymphoblastic Lymphoma+10 more
Medical College of Wisconsin40 enrolled1 locationNCT05794880
Recruiting
Phase 3

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Mixed Phenotype Acute LeukemiaLymphoblastic LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+3 more
Children's Oncology Group440 enrolled228 locationsNCT05602194
Recruiting
Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled230 locationsNCT03959085
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 2

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital128 enrolled2 locationsNCT06533748
Recruiting
Phase 4

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital850 enrolled3 locationsNCT06289673
Recruiting
Phase 3

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Lymphoblastic Lymphoma, Childhood
University Hospital Muenster683 enrolled228 locationsNCT04043494
Recruiting
Phase 1

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid LeukemiaNK-Cell LymphomaT-cell Acute Lymphoblastic Leukemia+1 more
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT05995028
Recruiting
Phase 2

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Lymphoblastic LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
University of Washington33 enrolled1 locationNCT07224100
Recruiting
Phase 1

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic Lymphoma
New York Medical College30 enrolled16 locationsNCT04972942